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The Em-Myc mouse is an extensively used model of MYC driven malignancy; however to
date there has only been partial characterization of MYC co-operative mutations leading
to spontaneous lymphomagenesis. Here we sequence spontaneously arising Em-Myc
lymphomas to deﬁne transgene architecture, somatic mutations, and structural alterations.
We identify frequent disruptive mutations in the PRC1-like component and BCL6-corepressor
gene Bcor. Moreover, we ﬁnd unexpected concomitant multigenic lesions involving Cdkn2a
loss and other cancer genes including Nras, Kras and Bcor. These ﬁndings challenge the
assumed two-hit model of Em-Myc lymphoma and demonstrate a functional in vivo role for
Bcor in suppressing tumorigenesis.
DOI: 10.1038/ncomms14581 OPEN
1 The Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia. 2 The Sir Peter MacCallum Department of Oncology, University of Melbourne,
Parkville, Victoria 3052, Australia. 3 Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia. 4 The Walter Eliza Hall Institute of
Medical Research, Parkville, Victoria 3052, Australia. 5 School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Clayton,
Victoria 3168, Australia. 6 Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. 7 Victorian Cancer Cytogenetics Service, St Vincent’s Hospital,
Fitzroy, Victoria 3065, Australia. 8 Department of Medicine, St Vincent’s Hospital, University of Melbourne, Parkville, Victoria 3052, Australia.
9 Developmental Biology Center, Masonic Cancer Center, and Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis,
Minnesota 55455, USA. 10 Australian Centre for Blood Diseases, Monash University, AMREP Building, Commercial Road, The Alfred Hospital, Melbourne,
Victoria 3004, Australia. 11 Cancer Biology and Therapeutics Department, John Curtin School of Medical Research, Australian National University, Canberra,
Australian Capital Territory 0200, Australia. * These authors contributed equally to this work. Correspondence and requests for materials should be
addressed to R.W.T. (email: Richard.Tothill@petermac.org) or to R.W.J. (email: Ricky.Johnstone@petermac.org).
NATURE COMMUNICATIONS | 8:14581 | DOI: 10.1038/ncomms14581 | www.nature.com/naturecommunications 1
G
enetically engineered mouse models (GEMMs) have
been extensively used to validate oncogene or tumour
suppressor function and serve as tractable models for pre-
clinical evaluation of new therapeutics1. Reminiscent of human
malignancies, considerable disease heterogeneity can be observed
in GEMMs despite the mostly inbred homozygous genotype and
their controlled housing environment2. Similar to humans, inter-
tumoural heterogeneity in GEMMs is likely caused by additional
somatic lesions that occur spontaneously and are required for
tumorigenesis. GEMMs in conjunction with high-throughput
genomics can therefore be used as ‘discovery’ resources to identify
and validate spontaneous co-operating mutations and thus
providing important information on the genetic interactions
that underpin tumour onset and progression3–6.
The Em-Myc mouse model employs a transgene mimicking
the t(8:14) translocation of cMyc and IgH enhancer elements
characteristic of human Burkitt lymphoma7. Em-Myc mice
develop B-cell leukaemia/lymphoma like malignancy with 100%
penetrance. Disease in these mice typically manifests as a period
of premalignant polyclonal precursor-B cell expansion followed
by self-limiting remission and onset of clonal lymphoid neoplasia
ranging from a pre-B to naive B phenotype8,9. Numerous articles
have been published using this model to interrogate the efﬁcacy
and mechanisms of action of diverse anti-cancer agents and to
study putative functional interactions between Myc and candidate
cancer causing genes. For example, a landmark study by Strasser
and colleagues using the Em-Myc model provided deﬁnitive
evidence that MYC and BCL2 can functionally cooperate to
accelerate lymphoma development10. In addition, the role of the
p19ARF-MDM2-p53 axis in regulating MYC-mediated apoptosis
and lymphomagenesis has been comprehensively dissected at
the genetic, biochemical and biological level using the Em-Myc
model11,12. Oncogenic RAS can also have an important co-
operative role in MYC transformation and spontaneous activating
Nras mutations were identiﬁed in Em-Myc lymphomas13. Taken
together, these studies highlight the utility of the model as a
cancer gene-discovery resource and its extensive application for
accurately studying the biology of the Myc oncogene.
Despite Em-Myc lymphomas being initiated by a single
oncogene on a deﬁned genetic background, there is a remarkable
degree of inter-tumour heterogeneity, reﬂected by gene expres-
sion proﬁling and the latency of disease onset14. This is consistent
with studies indicating that Em-Myc lymphomas arise through
acquisition of secondary or tertiary mutations that de-regulate
tumour suppressor pathways such as those mediated by p19ARF
and p53 that normally counteract the oncogenic effects of MYC.
The intrinsic apoptotic pathway is clearly implicated in Em-Myc
lymphomagenesis. Overexpression of Bcl2, forced expression of
other pro-survival BCL2 family members (for example, Bclxl,
Mcl1) or deletion of pro-apoptotic BH3-only genes (for example,
Bim, Bmf, Bad) can accelerate lymphoma development in the
Em-Myc mouse15–18. However, whether mutational dysregulation
of the BCL2 family actually occurs in spontaneously arising
tumours is not yet deﬁned. Disruption of non-apoptotic tumour
suppressive mechanisms are also implicated in Em-Myc
lymphomagenesis, in particular oncogene induced senescence
pathways19,20 and immune surveillance21. Despite clear evidence
that naturally occurring mutations in Trp53, Cdkn2a and Nras
co-operate with MYC in the Em-Myc model, other co-operating
de novo genetic lesions remain unknown in up to half of all
cases12. In particular, it is important to determine if disruption of
genes controlling disparate apoptotic and senescence pathways
that can co-operate with MYC, when synthetically de-regulated
are actually affected in spontaneously arising Em-Myc
lymphomas. We therefore used massively-parallel sequencing
to catalogue genetic lesions arising in Em-Myc lymphomas.
We found that in addition to the expected mutations or
deletions in Trp53, Cdkn2a and Nras, deleterious mutations in
BCL6-corepressor gene Bcor frequently occurred in Em-Myc
lymphomas. Subsequent functional studies conﬁrmed the
tumour suppressor role of Bcor, and Em-Myc lymphomas with
experimental depletion or deletion, or spontaneous mutation of
Bcor presented with a unique gene expression signature indicating
that TGFb signalling was aberrant in these lymphomas. Finally,
we discovered that Em-Myc lymphomas co-occur with loss of
Cdkn2a and either activating mutations in Ras or deleterious
mutations in Bcor providing evidence that loss of Cdkn2a alone
may not be sufﬁcient to cooperate with overexpressed Myc to
drive lymphomagenesis.
Results
Transgene architecture in El-Myc lymphoma. To comprehen-
sively characterize the genetic architecture of the Em-Myc
transgenic mouse, we applied whole-genome sequencing (WGS)
to a spontaneous Em-Myc lymphoma (#88) and its matching
germline DNA extracted from tail tissue of a hemizygous
transgenic animal. Augmenting the mouse reference genome with
the pUC12 vector sequence of the Em-Myc transgene enabled
mapping of break points within the transgene and enumeration of
transgene copy number in germline and lymphoma (Fig. 1a). We
identiﬁed all the expected elements of the transgene cassette
including the cloned translocation between chr12 (IgH enhancer)
and chr15 (Myc) in addition to the ﬂanking cloning sites within
the pUC12 vector DNA (ref. 7). A single breakpoint was detected
between chr19 and pUC12 vector sequence 50 of the Em-Myc
transgene. FISH analysis using ﬂuorescently labelled BAC probes
conﬁrmed juxtaposition of Myc and Jak2 (located on chr19)
proximal to transgene insertion on chr19, which is consistent
with observations from a previous study (Supplementary Fig. 1)22.
Copy-number analysis of WGS data revealed that ﬁve copies
of Myc were present in the hemizygous Em-Myc germline,
corresponding to three transgene copies and two endogenous
copies of Myc. We also observed a copy-number gain of aB3Mb
segment of chr19 proximal to site of transgene insertion (Fig. 1b),
as previously reported22. The chr19 segment plus one extra copy
of the Em-Myc transgene underwent further somatic gain (þ 1) in
the #88 Em-Myc lymphoma, which has not been previously
reported. Additional mate-pair WGS indicated that the transgene
copies are likely arranged as concatenated repeats (Fig. 1b).
We conﬁrmed germline ampliﬁcation of the chr19 segment in
Em-Myc transgenic mice bred at two additional institutions
(Walter and Eliza Hall Institute (WEHI) Melbourne Australia,
Cold Spring Harbor Laboratories USA) (Supplementary Fig. 2).
This indicates that these structural arrangements are almost
certainly founding events that occurred following the pronuclear
injection of the transgenic vector. The amplicon on murine chr19
is syntenic to the human 9p24.1 region, which is frequently
ampliﬁed in Hodgkin’s Lymphoma (HL) and primary mediastinal
B-cell lymphoma (PMBCL) and contains the tumour-promoting
genes JAK2 and CD274 (PD-L1)23. Fusello et al.22 previously
showed that pre-malignant and transformed B-cells from Em-Myc
mice exhibited higher PD-L1 expression compared with wild
type B-cells, concluding that this was causally related to the
chr19 ampliﬁcation. However, we found that PD-L1 protein
expression did not correlate with gene dosage inferred from
additional somatic gain of the chr19 amplicon (Supplementary
Fig. 3). We also found that Em-Myc lymphomas did not
show appreciable activation of JAK2 signalling as assessed
by phosphorylation of the downstream target STAT5 and
furthermore, JAK2 inhibition using FDA-approved small
molecule inhibitor ruxolitinib had no effect on survival of
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Em-Myc lymphomas cultured in vitro (Supplementary Fig. 4).
This suggests germline or somatic ampliﬁcation of Jak2 is unlikely
to contribute to initiation and maintenance of the Em-Myc
lymphomas. The role of other genes within the ampliﬁed chr19
region (for example, Il33, Pdcd1lg2) (Supplementary Data 1)
remains to be clariﬁed and is the subject of ongoing experiments.
WES identiﬁes new gene drivers of El-Myc lymphoma. We
next applied whole-exome sequencing (WES) to explore the
number, type and frequency of somatic mutations in 23
spontaneous Em-Myc lymphomas (Supplementary Data 2).
Sixteen cases were derived prospectively and seven cases were
taken from retrospectively archived lymphomas. WES of normal
tail DNA from Em-Myc animal #88 and a littermate control from
the prospective series (ML62) was used to ﬁlter germline
polymorphisms from the data. Furthermore, dbSNP annotated
variants or any single nucleotide variants (SNV) or insertion/
deletion (InDel) recurring two or more times in closely related
animals were removed from analysis as these variants were most
likely polymorphisms or recurrent sequencing artifacts. A subset
of SNVs and InDels were further validated using targeted
amplicon-based sequencing conﬁrming the high speciﬁcity of
92.6% (75/81) of our variant calling pipeline. Finally, to conﬁrm
the somatic driver mutations (described below) we sequenced
matching isolated circulating B-cells from individual mice at
4-weeks of age showing undetectable or very low-variant allele
frequency (VAF) compared with VAF measured in blood at
disease end point (Supplementary Fig. 5).
The lymphomas from the prospective cohort each had
3–31 SNVs or InDels predicted to truncate or alter the translated
amino acid sequence of proteins encoded by annotated genes
(Fig. 2a). As expected we detected Trp53 (n¼ 4) and Nras (n¼ 2)
mutations. In addition we identiﬁed Kras (n¼ 4) mutations that
have not been previously described in Em-Myc lymphomas
(Fig. 2b). The most frequently mutated gene was the BCL6-
copressor (Bcor), recurrently mutated in seven lymphomas (32%)
with either frameshift InDels or nonsense mutations predicted to
cause premature protein truncation. A splice-site variant in the
PRC2 complex subunit Ezh2, a gene previously shown to function
as a tumour-suppressor in the Em-Myc model24, was observed in
one case (ML33). Lymphoma ML39 harboured a mutation in the
gene Mtor affecting a residue conserved between mice and
humans and predicted to be damaging using SIFT algorithm.
Deregulation of the AKT-MTOR-eIF4E pathway has been shown
to co-operate with MYC in Em-Myc lymphomagenesis25
and treatment of Em-Myc transgenic mice with mTORC1
inhibition by everolimus during the pre-malignant stage of
disease signiﬁcantly delayed lymphoma onset20. Activating
MTOR mutations have also previously been described in several
human cancer types including diffuse large B-cell lymphoma26,27.
Lymphoma #88 harboured a mutation in mir142 that has
been reported in B20% of diffuse large B-cell lymphomas28.
Lymphomas ML352 and #299 had mutations in the ribosomal
protein Rpl10, a gene found recurrently mutated in T-ALL
(ref. 29). Three lymphomas (#218, #219, ML20) did not harbour
SNVs or InDels in genes that have any obvious link to cancer.
We analysed WES (n¼ 9) and low to medium coverage WGS
data (n¼ 13) (unpaired) to detect somatic copy-number altera-
tions (SCNAs) in lymphoma samples. Focal deletion events of
Cdkn2a were detected in ﬁve cases, validated by quantitative PCR
(Supplementary Fig. 6). Somatic ampliﬁcation of the Em-Myc
transgene and the proximal chr19 ampliﬁed region as shown for
lymphoma #88 (Fig. 1b), was evident in 8/22 tumours. We could
also detect recurrent ampliﬁcation and deletion events involving
known human cancer genes30 (Supplementary Data 3 and
Supplementary Fig. 7). Most of these SCNAs were characterized
by large segmental ampliﬁcations or whole chromosome
duplications involving chr3 (including Nras), chr6 (including
Kras), chr10, chr12, chr15 (including Myc) and chr18 and
monosomy or deletion of part of chr13. Focal SCNAs included
low-level gains on chr1 (Cxcr7) and chr7 (Fgfr2), and hemizygous
loss on chr4 (Psip1), chr9 (Nckipsd) and chr11 (Msi2). Taken
together these studies highlight the genetic diversity of individual
Em-Myc lymphomas and identify Bcor as the most frequently
mutated gene in this model of Myc-driven malignancy.
Tertiary driver mutations occur in El-Myc lymphomas.
A long-held paradigm established from previous studies using
the Em-Myc model was that a single co-operating lesion in the
b
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Figure 1 | Transgene architecture in El-Myc lymphoma. (a) Circos plot
showing the Em-Myc transgenic cassette (pUC12, phiX, chr12 (Em), chr15
(Myc), identiﬁed breakpoints and estimated copy number. Outer coloured
bars depict chromosome and transgene segments. Grey bars and links
represent germline copies with two copies per increment. Red bars
represent additional somatic copy-number gain and breakpoints.
(b) Schematic showing the arrangement of the Em-Myc transgene (upper),
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and the extra gain of the transgene and the segment of chr19 in lymphoma
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p19ARF-MDM2-p53 pathway or the RAS pathway would be
sufﬁcient to drive tumour development12,13,31. However, our data
challenges this hypothesis, at least with regard to the role of
Cdkn2a, as more than one putative ‘driver lesion’ could be
detected in some lymphomas. Examples include: (A) clone #6066
that harboured a Cdkn2a homozygous deletion and an activating
NrasQ61K mutation; (B) clone ML353 that carried a Cdkn2a
homozygous deletion along with an activating KrasQ61H point
mutation and (C) clone #4242 that had a Cdkn2a deletion and
Bcor frameshift deletion. These co-occurring lesions had similar
VAF in the individual samples that were validated by deep
targeted amplicon sequencing, suggesting they are likely to be
present in the dominant tumour clone rather than subclones
(Fig. 3). To validate the co-occurrence of multiple driver
mutations we transduced cells from two cultured Em-Myc
lymphomas (#6066 and #4242) with a retroviral barcode, sorted
single cells and expanded each clone in vitro. DNA sequencing
and qPCR CNV analysis of individual clones conﬁrmed a single
barcode integration and coalescing lesions in Cdkn2a and Bcor in
lymphoma #4242, and Cdkn2a and Nras lesions in lymphoma
#6066, conﬁrming that both genetic lesions detected in the two
lymphomas must be present in the same cell (Supplementary
Fig. 8).
A surprising ﬁnding from our sequencing of Em-Myc
lymphomas was the identiﬁcation of additional putative
oncogenic lesions in the context of Cdkn2a loss, namely for
lymphomas #4242 (Bcor frameshift deletion), ML353 (KrasQ61H)
and #6066 (NrasQ61K). To further determine if Em-Myc
lymphomas with knockout of one Cdkn2a allele not only lost
the second allele but also acquired additional mutations we
crossed Em-Myc to Cdkn2a knockout mice11 and sequenced
spontaneous Em-Myc;Cdkn2aþ / lymphomas. As expected
Em-Myc;Cdkn2aþ / mice demonstrated accelerated lympho-
magenesis compared with Em-Myc transgenic animals
(Supplementary Fig. 9). Further WES analysis of six Em-Myc;
Cdkn2aþ / lymphomas revealed that all had lost the wild type
Cdkn2a allele and one lymphoma harboured a heterozygous
pathogenic KrasQ61H mutation (VAF¼ 67%), indicating selective
outgrowth of an Em-Myc lymphoma with loss of INK4A/ARF and
expression of oncogenic Kras (Supplementary Fig. 10 and
Supplementary Data 4). Collectively, our data suggest that while
heterozygous loss of Cdkn2a creates a selective pressure resulting
in loss of the wild type Cdkn2a allele, it does not ameliorate
selective pressure for gain- or loss-of-function of other genes
outside the p53-axis. These data are consistent with a previous
report indicating that p19ARF inactivation is itself insufﬁcient to
trigger lymphomagenesis in Em-Myc transgenic mice32 and
indeed the authors of that study posited that ‘cryptic mutations
other than p19ARF loss accompany the conversion of
premalignant Em-Myc B cells’ in the Em-Myc;Cdkn2aþ /
setting. Herein we identify activating mutations in Ras and loss
of function mutations in Bcor as two such events.
Validating the tumour-suppressor function of Bcor. Protein
truncating BCOR mutations have previously been reported in
both solid and liquid human neoplasms33–35. The recurrence of
inactivating BCOR mutations in human tumours, a recent in vitro
study showing that BCOR regulates myeloid cell proliferation and
differentiation36 and our observations in the B-cell lineage
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Figure 2 | Somatic mutations detected by exome-sequencing of El-Myc lymphomas. (a) Mutation frequency across 23 Em-Myc lymphomas from a
prospective (n¼ 16) and retrospective series (n¼ 7). (b) Mutations identiﬁed in known cancer genes in Em-Myc lymphomas.
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described herein would strongly support a tumour-suppressive
function of this gene; however this has not been formally
demonstrated through functional in vivo studies. To experi-
mentally validate the tumour-suppressor function of Bcor in
Em-Myc lymphoma we knocked down or deleted Bcor using
shRNA or CRISPR-Cas9 methods, respectively, in Em-Myc
haematopoietic progenitor cells and transplanted them
into lethally irradiated syngeneic mice (Fig. 4a). We knocked
down or deleted Trp53 as a reference for expected
accelerated lymphomagenesis as well as including a negative
control (scrambled) shRNA and CRISPR sgRNA sequences. As
expected, Em-Myc lymphomagenesis was signiﬁcantly accelerated
when p53 was knocked down or deleted (Fig. 4b,c). Strikingly,
depletion or deletion of Bcor using similar techniques
signiﬁcantly accelerated lymphomagenesis demonstrating that
Bcor restrains Myc-induced lymphomagenesis (Fig. 4b,c).
Western blot analysis of Bcor depleted/deleted lymphomas
conﬁrmed the loss of Bcor protein expression (Fig. 4d,e).
Furthermore, RNA-seq analysis of Em-Myc lymphomas with
CRISPR-Cas9-mediated targeted deletion of Bcor showed
deletions or insertions proximal to the expected CRISPR-Cas9
trigger sequence in exon 4 that would be expected to cause Bcor
loss of function (Supplementary Fig. 11). These experiments
demonstrate, for the ﬁrst time, that Bcor can function in vivo
as a tumour suppressor gene, and plays an important role in Myc-
driven lymphomagenesis. To complement these studies,
we rescued loss of Bcor in the Bcor-mutant #4242 Em-Myc
lymphoma. We generated a traceable system introducing
wild type BCOR co-expressed with GFP by retroviral
transduction. Longitudinal proliferation studies in vitro
demonstrated that #4242 Em-Myc lymphomas ectopically
expressing wild type Bcor were negatively selected in a
competitive proliferation assay while expression of GFP alone
had no effect (Fig. 5a,b). This ﬁnding was conﬁrmed in a similar
experiment using the human Namalwa Burkitt lymphoma cell
line that expressed very low endogenous levels of BCOR
(Fig. 5c,d). Our novel functional data using Bcor depletion/
deletion unequivocally demonstrate that mutation of Bcor, seen
at a higher frequency in in Em-Myc lymphomas than lesions in
the known cancer genes Trp53, Cdkn2a and Ras, is a ‘driver’
oncogenic event and provides mechanistic context to
observations by others that mutations in BCOR occur in a
range of human malignancies.
Unique gene expression signature in BcorMut lymphomas.
BCOR has not previously been demonstrated to control tumour
cell proliferation or survival, so how BCOR loss co-operates with
MYC to drive oncogenesis remains unclear. We found that there
was signiﬁcant enrichment of IgM /IgD BcorMut lymphomas
in our tumour cohort (Supplementary Fig. 12). Nine lymphomas
with BCOR loss-of-function were IgM /IgD , while only one
was IgMþ /IgD . Eight BcorWT tumours were IgM /IgD ,
while 10 were IgMþ /IgD . We therefore conclude that Bcor
mutations are associated with an IgM /IgD proﬁle (Chi-
squared test, Po0.05). To begin to elucidate the underlying
biology of the Bcor-mutant lymphomas we applied RNA-seq
analysis of Em-Myc lymphomas with shRNA-mediated knock-
down of Bcor (Em-Myc;shBcor, n¼ 6) or Trp53 (Em-Myc;shp53,
n¼ 6); or Em-Myc lymphomas overexpressing NrasQ61K (Em-
Myc;NrasQ61K, n¼ 5). Gene expression proﬁling identiﬁed 393
signiﬁcantly differentially expressed genes in Em-Myc;shBcor
lymphomas compared with those with knockdown of p53 or
expressing oncogenic Nras (Supplementary Data 5). To deter-
mine if Em-Myc lymphomas with CRISPR/CAS9-mediated
knockout of Bcor (Em-Myc;sgBcor) or those harbouring sponta-
neous mutations in Bcor carried similar gene expression patterns,
we clustered gene expression data using the Em-Myc;shBcor sig-
nature gene set (Fig. 6). All sporadic Bcormutant lymphomas and
Em-Myc;sgBcor lymphomas clustered with the Em-Myc;shBcor
lymphomas. This demonstrates that BCOR loss-of-function,
either engineered or through spontaneous mutation, drives a
unique and reproducible transcriptional pattern in Em-Myc
lymphomas.
To determine if the BCOR loss-of-function gene expression
signature provides any molecular insight into the functional
interaction between MYC and BCOR we performed pathway
analysis using PANTHER. This identiﬁed upregulation of TGFb
signalling as the most affected molecular pathway in Em-
Myc;shBcor lymphomas (Bonferroni corrected P¼ 0.0058), with
enhanced expression of TGFb pathway members (Cited1, Bambi,
Acvr2b, Smad3, Mapk12, Tgfb2). The importance of TGFb
signalling in Em-Myc lymphomagenesis has been previously
reported, where this cytokine derived from macrophages in the
tumour microenvironment augmented oncogene-induced senes-
cence19. There it was shown that knockout of the senescence-
related histone methyltransferase Suv39h1 accelerated Myc-
driven lymphomagenesis with those lymphomas possessing an
enhanced TGFb signature reminiscent of the signature observed
in Em-Myc lymphomas with loss of Bcor. It was proposed that
TGFb drives Myc-induced senescence in a Suv39h1-dependent
manner raising the intriguing possibility that BCOR also regulates
this unique tumour suppressive mechanism.
Discussion
In summary, we have performed the ﬁrst comprehensive genome-
wide sequencing analysis of lymphoid malignancies arising in the
Em-Myc transgenic mouse model. Despite extensive use of the
model for cancer gene discovery through forward genetic
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approaches, we have discovered new co-operative genetic events
leading to spontaneous B-cell lymphomas. Our discovery of the
co-occurrence of multiple known driver mutations within a single
Em-Myc lymphoma suggests that individual clones evolve over
time, requiring multiple co-operative events to enable malignant
transformation or select for a more aggressive clone. Whether the
order of mutational events is important is not clear. However,
heterozygous Cdkn2a deletions do not completely ameliorate the
selective pressure for acquisition of mutations in other cancer
genes outside the p53-axis (for example, Nras, Kras, Bcor). We
identiﬁed a high-frequency of somatic Bcor mutations in Em-Myc
lymphomas and subsequently have shown that genetic disruption
of Bcor can accelerate Em-Myc lymphomagenesis. Among human
haematological cancers, BCOR mutations have been reported in
an array of cancer types including acute myeloid leukaemia and
myelodysplastic syndromes, chronic lymphocytic leukaemia and
acute lymphoblastic leukaemia (Supplementary Data 6). We have
shown experimentally, for the ﬁrst time, that Bcor can act as a
tumour suppressor gene and the distinct gene-expression
signature of Bcor-mutant lymphomas suggests that BCOR loss-
of-function may subvert TGFb signalling to drive lymphoma
development. Collectively our studies provide important infor-
mation on the genomic architecture of one of the most utilized
GEMMs, identiﬁes Bcor as a bona ﬁde tumour suppressor gene
and provides important information regarding the functional
interaction between Myc and p19ARF in the context of Em-Myc
lymphomagenesis.
Methods
El-Myc Lymphomas. All animal work was performed with approval from the
Peter MacCallum Cancer Centre Animal Experimentation Ethics Committee.
A prospective series of sixteen heterozygote Em-Myc mice originally obtained
from the Walter and Eliza Hall Institute (Melbourne, Australia) on a C57BL/6
background were bred for discovery analysis and a retrospective series of seven
lymphomas were collated from archived laboratory resources. The age and gender
of mice used in the study are detailed in Supplementary Table 1. Matched normal
tail tissue was available for lymphoma #88 and a littermate control ML62.
We collected peripheral blood for isolation of B-cells from 4-weeks of age and at
2-week intervals until the mice were sacriﬁced with advanced disease.
Nucleic acid extraction. DNA was extracted using the DNeasy blood and tissue
kit (Qiagen, Hilden, Germany), RNA was extracted using the miRNeasy mini kit
(Qiagen) and nucleic acids were quantiﬁed by spectrophotometer. RNA integrity
was assessed using the Agilent Bioanalyzer 2100 (Agilent, CA, USA).
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Whole-genome sequencing. Approximately 1 mg of gDNA was prepared for
fragment-sequencing libraries and then processed according to standard protocols
using TruSeq chemistry (Illumina, San Diego, CA, USA). Mate-pair libraries were
prepared using Nextera Mate Pair Sample Prep Kit according to manufacturers
instructions (Illumina, San Diego, CA, USA). Paired-end sequencing (2 100 bp)
on HiSeq2000 (Illumina) was applied to achieve 1-30-fold mapped read coverage
across the entire genome depending on required depth (Supplementary Data 7).
Reads were aligned using Bowtie2 v2.1.0 (Langmead and Salzberg 2012) to mouse
reference genome mm10 (Dec. 2011 GRCm38/mm10). Duplicates were identiﬁed
and removed from the aligned data using Picard’s Mark Duplicates v1.89 (Broad
Institute, Boston, MA, USA). BreakDancer v1.3.5 (ref. 37), CREST v0.0.1 (ref. 38)
and Socrates v0.9.5 (ref. 39) were employed to identify structural variants. Whole
genome de novo assembly was undertaken using Gossamer40 to compare resulting
contigs with the genomic sequence relevant to the transgene. Control-FREEC
(ref. 41) was used to call somatic copy-number alterations using tail88 as the
germline control. A window size of 50,000 bp was used.
Exome sequencing. Approximately 1 mg of gDNA prepared as above was
processed for whole exome-capture resequencing according to standard protocols
(Agilent Technologies, Santa Clara, CA, USA) on a HiSeq 2000 achieving a mean
sequence depth of 110-fold and at least 10-fold coverage in 98% of targeted bases
(Supplementary Data 8). Variant calling methods were based on Genome Analysis
Tool Kit (GATK)42 muTect43 and Strelka44. An intersection of variant callers was
used to optimize speciﬁcity and sensitivity by including only SNVs called by
muTect and one other method or any InDel called by at least two methods.
Variants were annotated using the ENSEMBL database45. Somatic copy-number
calls from exome data were generated using ADTEx (ref. 46) against three
independent lymphoma samples.
RNA sequencing and data analysis. Approximately 1 mg of RNA was used to
generate polyA enriched cDNA libraries using TruSeq sample preparation kit
(Illumina, San Diego, CA, USA) and paired-end RNA-sequencing (2 50 bp) was
performed on the HiSeq 2000, generating 4 107 reads per sample. Reads were
quality checked using FastQC and trimmed if necessary for low base quality or
adaptor using Cutadapt v1.6 (ref. 47). RNA-sequencing reads were aligned using
the short read aligner software – TopHat48. The raw RNA-sequencing data was
converted to feature counts using HTSeq software package allowing generation of
expression matrices collating read counts per gene based on ENSEMBL
annotation45. EdgeR v3.0 (Bioconductor, Fred Hutchinson Cancer Research
Center, Seattle, WA, USA) statistical software was used in the statistical
programming tool R (http://www.r-project.org/) to normalize gene expression and
perform statistical analysis by linear regression49. Gene Cluster 3.0 was used to
cluster samples and genes by average linkage centred clustering. Cluster diagrams
and heat maps were visualized and then exported from Treeview v1.1.6r2. Pathway
mapping of signiﬁcant genes (P value o0.05) was undertaken using PANTHER
pathway analysis software50.
Variant validation by amplicon-based gene sequencing. Targeted amplicon-
based massively-parallel sequencing was used to validate mutations detected by
exome-sequencing and for analysis of serial blood samples. PCR Primers were
designed ﬂanking mutated bases incorporating a 5-prime extended universal
sequence for secondary PCR enabling addition of full-length lllumina adaptors
(Supplementary Data 9). Primary PCR reaction mixture included 10 ng genomic
DNA template, 10ml of 2 Phusion high-ﬁdelity PCR master-mix (New England
Biolabs, Ipswich, UK), 2.5 ml of 4 mM forward and reverse oligonucleotide primers
and made up to contain a total reaction volume of 20 ml with PCR-grade H2O.
The PCR reaction mixture was cycled at 95 C for 2min, (95 C for 30 s 68 C (and
decreasing 1 C every cycle) for 30 s, 72 C for 30 s) for 9 cycles, (95 C for 30 s,
61 C for 30 s, 72 C for 30 s) for 32 cycles and 72 C for 5min. PCR products were
then pooled and combined with AMPure XP magnetic beads (Beckman Coulter,
Pasadena, CA, USA) in a ratio of 1:0.9 and then puriﬁed as per manufacturer
protocol. Puriﬁed pooled amplicons were diluted 1:100 in PCR-grade H2O
and prepared in PCR reaction mix of 1 ml template DNA, 10ml of 2Phusion
high-ﬁdelity PCR master-mix, 2.5 ml of 4 mM forward and reverse oligonucleotide
primers and made up to contain a total reaction volume of 20 ml with PCR-grade
H2O. The PCR-reaction mix was then subject to an additional PCR cycle using
indexed Fluidigm CS1 and CS2 primers (Fluidigm, CA, USA) at conditions of
95 C for 5min, (95 C for 15 s, 60 C for 30 s, 72 C for 1min) for 15 cycles and
72 C for 3min. Secondary PCR products were then puriﬁed using AMPure XP
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Figure 5 | Bcor re-expression in a Bcor null El-Myc cell line. (a) 4242 cells (Bcor null) were transduced with either MSCV inert vector or MSCV;Bcorwt and
FACS sorted into a ratio of 50:50 with the non-transduced parental cell line. The GFP population was monitored over time and demonstrated that forced
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transduced with the inert vector.
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magnetic beads as previously described. Puriﬁed DNA was quantiﬁed and loaded
on MiSeq (2 150bp) (Illumina, CA, USA) at 6 rM and produced a yield of
B4.5–5Gb. Custom ports on the MiSeq cartridge were used to incorporate the
custom sequence tagged (CS) Fluidigm primers CS1 (50-ACACTGACGACATGG
TTCTACA-30) (port 18, read 1), CS2RC (50-AGACCAAGTCTCTGCTACC
GTA-30) (port 19, index read) and CS2 (50-TACGGTAGCAGAGACTTGGTCT-30)
(port 20, read 2), which were used at a ﬁnal concentration of 0.5 mM. Amplicon
sequencing data were aligned using bwa-mem (v0.7.12) to the mouse reference
genome (GRCm38). A list of regions of interest (ROIs) was compiled as a union set
of all expected variants in the EuMyc mice. Pileup data were generated using
samtools (v1.1) over the ROIs. Read depth and the number of reads supporting
each of the expected variants were extracted from pileup data. Varscan (v2.3) was
used for variant calling to identify potential variants outside the ROIs.
Cellular barcoding. A degenerate 16 nucleotide sequence was designed to
theoretically provide 4,194,304 unique barcodes for cell tracking. A PhiX DNA
spacer sequence (138 bp) plus ﬂanking 50 and 30-prime universal priming sites
(CS1 and CS2, 22 bp each) were incorporated to enable PCR ampliﬁcation and
direct DNA sequencing of barcodes. PCR primers designed complimentary to CS1
and CS2 and harbouring 50-prime XhoI and EcoRI restriction sites enabled
sequential PCR ampliﬁcation and then digestion of the double stranded DNA
barcoded fragment for directional shotgun cloning into an MSCV-IRES-BFP
retroviral plasmid. A complex pool of recombinant MSCV-Barcode plasmid was
used to generate retrovirus in HEK293T cells in combination with the pAMPHO
viral packaging vector (ClonTech). Em-Myc Cell lines #6066 and #4242 were
transduced at 0.2 multiplicity of infection. Transduced cells were single cell sorted
by BFP expression and deposited into single wells of a 96-well plate containing
culture media using a BD FACSAria Fusion (BD Biosciences). Em-Myc clones were
grown by cell culture expanding to B106 cells followed by genomic DNA
extraction by column chromatography (Qiagen). Barcode sequences were ampliﬁed
from genomic DNA by PCR using Phusion master mix (NEB) with CS1 and
CS2 primers using 28-cycle reaction (Appendix 3B). Barcodes were then sequenced
by Sanger sequencing from CS2 primer.
Western blot antibodies. Western blot analysis was performed using
afﬁnity-puriﬁed rabbit-a-Bcor51 used at 1:3,000, mouse-a-phospho-p44/42
MAPK (Erk1/2) clone E10 #9106 (Cell Signaling Technology) used at 1:1,000,
rabbit–a-phospho-STAT5 (Tyr694) clone D47E7 #4322 (Cell Signaling
Technology), used at 1:1,000, rabbit–a-STAT5 #9363 (Cell Signaling Technology)
used at 1:1,000, rabbit–a-phospho-JAK2 (Tyr1007/1008) #3771 (Cell Signaling
Technology), used at 1:1,000, rabbit-a-JAK2 clone D2E12 #3230 (Cell Signaling
Technology), used at 1:1,000, rabbit–a-phospho-S6RP (Ser240/244) #2215
(Cell Signaling Technology) used at 1:1,000, mouse-a-atubulin clone DM1A
#MABT205 (Merck Millipore) used at 1:5,000, rabbit-a-HSP90 #4874 (Cell
Signaling Technology) used at 1:5,000 or mouse-a-bActin clone AC-74 #A2228
(Sigma Aldrich) used at 1:5000. Secondary antibodies used were polyclonal
rabbit-anti-mouse-HRP #P026002-2 (Dako) used at 1:10,000 and polyclonal
swine-anti-rabbit-HRP #P039901-2 (Dako) used at 1:10,000.
Original western blots that correspond to blots shown in Figs 4 and 5 are shown
in Supplementary Figs 13 and 14.
Viral transduction. Calcium phosphate transfections of packaging cell lines
were used to generate retroviral supernatant for vectors pLMS-Bcor.sh9,
pLMS-Trp53.sh1224, pLMS-Scram, MSCV-Nras.Q61K, MSCV-empty,
MSCV-Bcor, pCIG-BcorG2, pCIG-Trp53(b) or pCIG-Scram (Supplementary
Table 2). Em-Myc fetal cells were incubated with the retroviral supernatant and
appropriate media to facilitate retroviral transduction with GFP positivity of the
cells used as marker of transduction efﬁciency. Irradiated recipient C57BL/6 mice
received 106 transduced GFP expressing cells via intravenous injection37 and
analysis of tumour latency was performed. Cell lines #4242 and Namalwa were
incubated with retroviral supernatant containing MSCV-empty or MSCV-Bcor.
Cells transduced with MSCV-Bcor or MSCV-empty vector were sorted and
combined with non-transduced parental lines in a 50:50 ratio of GFP-positive to
GFP-negative cells. Human cell lines were sourced from the American Type
Culture Collection (ATCC).
Data availability. The datasets generated during and/or analysed during the
current study have been deposited in the NCBI SRA (http://www.ncbi.nlm.nih.gov/
sra) database under accession code SUB2009648. The authors declare that all data
supporting the ﬁndings of this study are available within the article and its
supplementary information ﬁles or from the corresponding author on reasonable
request.
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